title: Efficacy studies on a canarypox-rabies recombinant virus.
abstract: Recombinant avipox viruses have been developed expressing the rabies glycoprotein gene. A fowlpox-rabies recombinant has previously been shown to be protective against live rabies virus challenge in a number of non-avian species. This report describes the development of a canarypox-rabies recombinant. A comparison is made of the protective efficacy of this recombinant with other pox-rabies recombinants.
authors.affiliation: Virogenetics Corporation, Troy, New York 12180.
authors.forename: J
authors.initials: J
authors.lastname: Taylor
authors.forename: C
authors.initials: C
authors.lastname: Trimarchi
authors.forename: R
authors.initials: R
authors.lastname: Weinberg
authors.forename: B
authors.initials: B
authors.lastname: Languet
authors.forename: F
authors.initials: F
authors.lastname: Guillemin
authors.forename: P
authors.initials: P
authors.lastname: Desmettre
authors.forename: E
authors.initials: E
authors.lastname: Paoletti
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002415:Cats; D004274:DNA, Recombinant; D004285:Dogs; D051379:Mice; D011212:Poxviridae / Q000235:genetics* / Q000276:immunology; D011818:Rabies / Q000517:prevention & control*; D011820:Rabies virus / Q000235:genetics / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D004274:DNA, Recombinant; D014614:Vaccines, Synthetic; D014765:Viral Vaccines